The company's pipeline includes potential treatments for recessive dystrophic epidermolysis bullosa (RDEB), Batten Disease and Sanfilippo Syndrome.

Abeona trades on the Nasdaq exchange (symbol: $ABEO), and completed post-IPO equity fundraising in October 2017, raising $92 million.